CN1913911A - 功能性饮料及组合物 - Google Patents
功能性饮料及组合物 Download PDFInfo
- Publication number
- CN1913911A CN1913911A CNA2005800038099A CN200580003809A CN1913911A CN 1913911 A CN1913911 A CN 1913911A CN A2005800038099 A CNA2005800038099 A CN A2005800038099A CN 200580003809 A CN200580003809 A CN 200580003809A CN 1913911 A CN1913911 A CN 1913911A
- Authority
- CN
- China
- Prior art keywords
- methyl
- functional drinks
- catechuic acid
- acid
- allergic rhinitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 35
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 35
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000005577 familial hyperlipidemia Diseases 0.000 claims abstract description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 235000013361 beverage Nutrition 0.000 claims description 55
- -1 methyl catechuic acid Chemical compound 0.000 claims description 45
- 229950001002 cianidanol Drugs 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 7
- 241001423651 Buchnera americana Species 0.000 claims description 6
- 235000008542 Colubrina ferruginosa Nutrition 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 5
- 230000037213 diet Effects 0.000 claims description 5
- 235000010724 Wisteria floribunda Nutrition 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 210000003928 nasal cavity Anatomy 0.000 claims description 3
- 229940100662 nasal drops Drugs 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 241001660756 Guettarda scabra Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 abstract description 14
- 235000020824 obesity Nutrition 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 9
- 239000001257 hydrogen Substances 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 3
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 150000001765 catechin Chemical class 0.000 abstract 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 abstract 1
- 235000005487 catechin Nutrition 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 38
- 239000003925 fat Substances 0.000 description 30
- 230000007935 neutral effect Effects 0.000 description 28
- 230000000694 effects Effects 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 20
- 235000013305 food Nutrition 0.000 description 14
- 239000000284 extract Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010048908 Seasonal allergy Diseases 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical class C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 8
- 206010003210 Arteriosclerosis Diseases 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 241001122767 Theaceae Species 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 244000117493 Colubrina ferruginosa Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 206010039083 rhinitis Diseases 0.000 description 5
- 244000050510 Cunninghamia lanceolata Species 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000234479 Narcissus Species 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 208000010643 digestive system disease Diseases 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000024557 hepatobiliary disease Diseases 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010352 sodium erythorbate Nutrition 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000014112 Cassia mimosoides Nutrition 0.000 description 1
- 244000302899 Cassia mimosoides Species 0.000 description 1
- 244000235531 Cupressus funebris Species 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 241000209051 Saccharum Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- BPJYAXCTOHRFDQ-UHFFFAOYSA-L tetracopper;2,4,6-trioxido-1,3,5,2,4,6-trioxatriarsinane;diacetate Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].CC([O-])=O.CC([O-])=O.[O-][As]1O[As]([O-])O[As]([O-])O1.[O-][As]1O[As]([O-])O[As]([O-])O1 BPJYAXCTOHRFDQ-UHFFFAOYSA-L 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/163—Liquid or semi-liquid tea extract preparations, e.g. gels, liquid extracts in solid capsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Birds (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyrane Compounds (AREA)
Abstract
本发明提供一种可抑制过敏性鼻炎,而且,对于高脂血症及其派生疾患即动脉硬化症、肥胖症、肝疾患的预防·治疗有效的功能性饮料及组合物。含有作为过敏性鼻炎抑制剂及抗高脂血症的有效成分量的下述化学式(1)所示的甲基儿茶酸。化学式(1)[R1、R2、R3、R4各自独立地是氢原子、甲基中的任一个,X1、X2各自独立地是氢原子、羟基中的任一个] 。
Description
技术领域
本发明涉及含有对过敏症状的抑制及对高脂血症及其派生疾患,即动脉硬化症、肥胖症、肝胆疾患的预防·治疗有效的成分的功能性饮料及组合物。
背景技术
作为一种过度的免疫反应,过敏是由于植物、动物、微生物、食物、化学物质等称为“变应原”的原因物质所引发的。特别地,过敏性鼻炎是以花粉症为代表的上呼吸道过敏疾患,表现打喷嚏、水样鼻液、鼻塞等症状。据说日本全国仅花粉症患者就有1300万人,已成为重大的社会问题。为了抑制过敏症状,需要抑制组胺等引起过敏症状的化学传导物质从肥大细胞中的释放。为了抑制组胺的释放,一直在开发各种抗过敏剂。
例如,对含有从乌龙茶中提取的提取物作为抑制特应性皮炎等过敏反应的有效成分的抗过敏剂、或将抗组胺剂与从杉树中榨取的油混合的物质作为杉树花粉症的预防药及治疗药使用的物质等进行了研究(参照专利文献1、2)。另外,还对将草药与日本茶混合的花粉症补饮进行了研究(参照专利文献3)。
另外,近年随着饮食生活的欧美化,以高脂血症、糖尿病、高血压、肥胖为代表的生活习惯病有逐渐增加的倾向。例如,据说日本人中2/3死于生活习惯病,已成为巨大的社会问题。其中的高脂血症是以饮食的高热量化、运动不足、基础代谢低等各种因素为起因的血液中的中性脂肪值或总胆固醇值升高的疾患,已知特别是中性脂肪值的升高成为各种重度疾患,即派生疾患的起因。
中性脂肪值的升高促进脂肪细胞的肥大、肝细胞的中性脂肪蓄积及动脉硬化易发性的脂蛋白增加。而脂肪细胞的肥大对于肥胖症,肝细胞的中性脂肪蓄积对于经脂肪肝的肝炎或肝硬化的发病危险增高。另外,所说的动脉硬化易发性脂蛋白是指,残粒样脂蛋白-胆固醇和小粒子LDL-胆固醇,由于这些物质容易被巨噬细胞或血管内皮细胞吸收,所以血中浓度的增加使动脉硬化的发病危险增高。
也就是说,将血液中的中性脂肪值控制在健康范围内与抑制高脂血症派生疾患的动脉硬化症、肥胖症、肝病等的发病有关。因此,一直在开发预防高中性脂肪血症的各种药物和食品等。
例如,已经知道,由于证实了茶叶中的儿茶酸类具有抗氧化作用、动脉硬化抑制作用、血压上升抑制作用、血糖上升抑制作用等多种作用,因此通过将茶叶粉末等用于健康食品的原料,提高基础代谢,促进脂肪燃烧来预防肥胖(非专利文献1)。
专利文献1:特开平10-175874号公报
专利文献2:特开2002-234846号公报
专利文献3:特开2001-348339号公报
非专利文献1:村松敬一郎编“茶の科学”朝仓书店(2002)
发明内容
发明要解决的问题
但是,专利文献1中记载的提取物不能抑制鼻炎的症状,另外,专利文献2中记载的预防及治疗药物在杉树花粉进入体内时不能发挥效果。进一步,由于该预防及治疗药物与抗组胺剂混合时诱发困倦等副作用,因此不适于经常服用。另外,专利文献3中记载的花粉症补饮,由于使用了草药,而产生独特的味道,不是对所有人都适合。
并且,已知儿茶酸类对于如上述的促进脂肪燃烧、预防肥胖症是有效的。但是,关于对过敏症状的抑制和对高脂血症及其派生疾患的预防或治疗两者都有效的药物或饮食品还没有被提出。由于过敏症状和高脂血症是完全不同的疾病,很难考虑到对两者都有效的物质。另外,茶叶根据其种类的不同所含有的化学成分不同,而且,其种类也是多样的。其中儿茶酸类有很多异构体,因此研究哪种儿茶酸对于哪种疾病有效与否是困难的。
本发明就是鉴于以上的课题而进行的,目的是提供能抑制过敏性鼻炎并且对于高脂血症及其派生疾患有预防或治疗效果的功能性饮料及组合物。
解决问题的方法
为了达到上述目的,本发明人等反复深入研究,结果发现,某些种类的茶叶中存在着能抑制过敏性鼻炎并且对于高脂血症及其派生疾患具有预防或治疗效果的儿茶酸成分,从而完成了本发明。
更具体地,本发明提供了如下的技术方案。
(1)含有下述化学式(1)表示的甲基儿茶酸的功能性饮料,含有作为过敏性鼻炎抑制剂、抗高脂血症剂及肝胆功能改善剂的有效成分量的所述甲基儿茶酸。
……化学式(1)
[R1、R2、R3、R4各自独立地是氢原子、甲基中的任一个,X1、X2各自独立地是氢原子、羟基中的任一个。]
根据(1)的发明,通过使饮料中含有有效成分量的甲基儿茶酸,可以抑制过敏性鼻炎及预防或治疗高脂血症及其派生疾患。如上所述,儿茶酸类具有抗氧化作用、动脉硬化抑制作用、血压升高抑制作用、血糖升高抑制作用、杀菌作用、抗菌作用、除臭作用等多种效果。
其中,化学式(1)表示的甲基儿茶酸在这些作用效果中,特别是抗过敏作用和减少中性脂肪的效果良好。通过减少中性脂肪,残粒样脂蛋白-胆固醇和LDL-胆固醇的生物合成受到抑制因而预防了动脉硬化,进而,由于抑制了脂肪细胞的中性脂肪蓄积而减少了肥胖症的发病危险。
另外,中性脂肪被肝脂肪酶分解成脂肪酸和甘油而被肝细胞吸收,因此血清中的中性脂肪值的升高使脂肪肝、进而肝炎和肝硬化的危险增高,根据(1)的发明,通过在甲基儿茶酸饮料中含有有效成分量,中性脂肪值受到抑制,因此可以预防这些肝胆功能障碍。
这里,所说的“过敏”是指,对侵入生物体内的异物进行攻击的抗体过量产生,使正常细胞被卷入而发生的过度的免疫反应。过敏反应有多种类型。例如,IgE抗体引起的过度反应中,对于某些特定的变应原(花粉、蛋白质、跳蚤、室内尘土等)产生反应的IgE抗体过量产生,附着于肥大细胞表面。变应原再次到达此处时,抗体交联,肥大细胞被活化,释放出作为化学传导物质的组胺、白三烯等炎症物质,引起花粉症、鼻炎、特应性皮炎、荨麻疹和哮喘等。所说的花粉症是,在眼或鼻等的粘膜处发生炎症等的症状。
另外,所说的“过敏性鼻炎”是指,由于摄取或接触某些种类物质而在生物体内产生抗体,通过再摄取或再接触相同物质而发生抗原抗体反应,表现出疾病症状的过敏性疾患的一种,特别是指对于花粉或室内尘土等抗原作为过敏反应在鼻粘膜发生的炎症。具有代表性的有,杉树或扁柏等的花粉引起的花粉症或跳蚤、室内尘土引起的全年性的过敏等。
另外,所说的“过敏性鼻炎抑制剂”是指,对于如上所述的过敏性鼻炎的症状产生抑制效果的物质。另外,本发明中所说的抗高脂血症剂、抗肥胖剂、肝疾患治疗剂是指,各自对高脂血症、肥胖症、肝疾患产生预防或治疗效果的物质。根据本发明,由于这些效果是来自本发明涉及的甲基儿茶酸,因此本发明涉及的甲基儿茶酸就是本发明涉及的“过敏性鼻炎抑制剂”、“抗高脂血症”及“肝胆功能改善剂”。而且,本发明涉及的功能性饮料在某种意义上是指,可以同时产生这些效果的物质。
另外,所说的“高脂血症”的意思是,使血清中的中性脂肪或胆固醇大于等于基准值的疾患,其派生疾患则有动脉硬化症、肥胖症、包括脂肪肝的肝疾患。已经知道,肥胖症进一步成为糖尿病或高血压症等生活习惯病的起因。
另外,所说的“有效成分量”是指,判断抑制过敏症状及中性脂肪值的有效成分产生充分效果时的含量。具体地,每100ml饮料含有1mg~30mg甲基儿茶酸。
(2)根据(1)中记载的功能性饮料,其中上述功能性饮料是提取茶叶而得到的饮料。
根据(2)的发明,借助提取茶叶得到的物质,通过喝茶这样的日常生活中的行为,就可以容易地抑制过敏性鼻炎,并且预防高脂血症、肥胖症、肝胆疾患等生活习惯病。(2)的发明涉及的饮料可以是将提取物装在罐、PET瓶等中得到。
(3)根据(1)或(2)中记载的功能性饮料,其中,在所述功能性饮料每100ml中含有1mg~30mg所述甲基儿茶酸。
根据(3)的发明,通过使100ml饮料中的甲基儿茶酸的含量为上述含量,可以提供苦味少且易饮用的饮料。由于甲基儿茶酸的含量大于30mg时苦涩味增加,因此不适用于饮料。另外,小于1mg时不能产生充分的效果。
(4)根据(1)至(3)中的任一项记载的功能性饮料,其中,上述甲基儿茶酸是来源于“红富贵(べにふうき)”、“红富士(べにふじ)”、“红誉(べにほまれ)”、“八重穗(やえほ)”、“骏河早生(するがわせ)”、“丰绿(ゆたかみどり)”、“金谷绿(かなやみどり)”、“奥武藏(おくむきし)”、“青心大有(青心大パン)”、“青心乌龙(青心烏龍)”、“红花(紅花)”、“红光(べにひかり)”、“山峡(やまかい)”、“山绿(やまみどり)”、“唐红(からべに)”、“香骏(香駿)”、“仓风(そうふう)”及“奥绿(おくみどり)”或它们的混合物的茶叶。
根据(4)的发明,由于甲基儿茶酸是“红富贵”、“红富士”、“红誉”、“八重穗”、“骏河早生”、“丰绿”、“金谷绿”、“奥武藏”、“青心大有”、“青心乌龙”、“红花”、“红光”、“山峡”、“山绿”、“唐红”、“香骏”、“仓风”及“奥绿”等品种的茶叶中固有的物质,因此通过使用这些茶叶,可以抑制过敏性鼻炎并且抑制中性脂肪。另外,作为含有甲基儿茶酸的茶叶举出了上述品种的茶叶,但不限于这些品种。
(5)根据(1)至(4)中的任一项记载的功能性饮料,其中,上述功能性饮料被附加了为抑制过敏性鼻炎而使用的意思表示和/或因对于高脂血症、肝胆功能改善有效而使用的意思表示。
根据(5)的发明,通过附加了为抑制过敏性鼻炎而使用的意思表示和/或因对于高脂血症、肝胆功能改善有效而使用的意思,可以给消费者留下饮料效能的印象。
(6)含有下述的化学式(1)表示的甲基儿茶酸的组合物,含有作为过敏性鼻炎抑制剂及抗高脂血症剂的有效成分量的所述甲基儿茶酸。
……化学式(1)
[R1、R2、R3、R4各自独立地是氢原子、甲基中的任一个,X1、X2各自独立地是氢原子、羟基中的任一个。]
根据(6)的发明,通过使组合物中含有有效成分量的甲基儿茶酸,可以抑制过敏性鼻炎及减少中性脂肪。另外,由于也可以以饮料以外的形态摄取,因此可以根据症状或用途、目的制造商品。
这里,所说的“组合物”是指,向本发明涉及的茶叶中提取的提取物中添加以往公知的添加剂而得到的物质。该组合物还包括为人及动物的饮食用而制造的物质。不限于固形物,也可以是具有流动性的液体或凝胶等。该组合物包括食品,例如,可以将含有本发明涉及的“过敏性鼻炎抑制剂”、“抗高脂血症剂”的营养补品作为食品提供,也可以制成片剂的形状。
(7)根据(6)中记载的组合物,其中,上述组合物是饮食品、内服药、涂布药、鼻腔清洗剂、滴鼻药、化妆品或眼睛的清洗剂。
根据(7)的发明,通过使组合物成为上述的物质,可以更直接地摄取甲基儿茶酸。
发明的效果
根据本发明涉及的功能性饮料,可以抑制过敏性鼻炎,不诱发困倦等副作用,而且具有适合所有人的味道。另外,可以在抑制过敏性鼻炎的同时,抑制中性脂肪的蓄积。因此,通过喝茶这样的日常生活中的行为,就可以容易地抑制过敏性鼻炎,并且预防高脂血症、肥胖症、肝胆疾患等生活习惯病。
附图说明
图1是表示由各受试者的日志算出的外观的鼻炎重症度的图。
图2是表示各受试者的鼻液中的嗜曙红细胞数的变动量的图。
图3是表示各受试者的血中中性脂肪量的变动量的图。
图4是表示各受试者的总胆红素的变动量的图。
具体实施方式
以下,对于本发明进行详细说明。
功能性饮料的制造
本发明涉及的功能性饮料是,以来源于下述记载的规定的茶叶的甲基儿茶酸成分作为过敏性鼻炎抑制有效成分及中性脂肪减少剂的功能性饮料。通过饮用热水浸泡该茶叶得到的茶,可以抑制过敏性鼻炎并可以减少中性脂肪。
本发明涉及的“甲基儿茶酸”是指,化学式(1)表示的物质,是甲基化的儿茶酸及精制时不可缺少的成分。本发明中的甲基儿茶酸主要是,优选含有表没食子儿茶酸-3-O-(3-O-甲基)桔酸酯(以下称为EGCG3”Me)、表儿茶酸-3-O-(3-O-甲基)桔酸酯(以下称为ECG3”Me)、表儿茶酸-3-O-(4-O-甲基)桔酸酯(以下称为ECG4”Me)、表没食子儿茶酸-3-O-(4-O-甲基)桔酸酯(以下称为EGCG4”Me)、没食子儿茶酸-3-O-(3-O-甲基)桔酸酯(以下称为GCG3”Me)、儿茶酸-3-O-(3-O-甲基)桔酸酯(以下称为CG3”Me)、儿茶酸-3-O-(4-O-甲基)桔酸酯(以下称为CG4”Me)、或没食子儿茶酸-3-O-(4-O-甲基)桔酸酯(以下称为GCG4”Me)及它们的异构体。甲基儿茶酸的一般性的效果是,阻止作为化学传导物质的组胺等炎症物质的释放,抑制I型、IV型过敏反应。
……化学式(1)
这里,EGCG3”Me、ECG3”Me、ECG4”Me、EGCG4”Me、GCG3”Me、CG3”Me、CG4”Me、或GCG4”Me的含量,优选在每100ml饮料中为1~30mg。更优选2~20mg,进一步优选5~15mg。含量少于1mg时,抑制过敏性鼻炎症状的效果及抑制中性脂肪的效果下降。含量多于30mg时,“苦涩味”增加,不适于饮用。这里,如果有可消除该“苦涩味”的方法,有时含量也可以多于30mg。另外,关于含量,应该根据甲基儿茶酸的种类适当调制。
另外,本发明涉及的甲基儿茶酸是来源于规定的茶叶。作为含有甲基儿茶酸的茶叶可以举出“红富贵”、“红富士”、“红誉”、“八重穗”、“骏河早生”、“丰绿”、“金谷绿”、“奥武藏”、“青心大有”、“青心乌龙”、“大叶乌龙”、“凤凰单丛”、“凤凰水仙”、“白叶单丛水仙”、“黄枝香”、“武夷水仙”、“红花”、“红光”、“山峡”、“山绿”、“唐红”、“香骏”及“奥绿”或它们的混合物或它们的混合物。这些茶叶可以使用单一种类或复数种类混合使用。
另外,本发明涉及的功能性饮料,为了使上述的甲基儿茶酸发挥充分的抑制过敏性鼻炎的效果及抗高脂血症的效果,可以与防氧化剂、香料、各种酯类、有机酸类、有机酸盐类、无机酸类、无机酸盐类、无机盐类、色素类、乳化剂、保存剂、调味剂、甜味剂、酸味剂、果汁提取物类、蔬菜提取物类、花蜜提取物类、pH调节剂、品质稳定剂等添加剂单独混合或并用混合。
例如,作为甜味剂可以举出砂糖、葡萄糖、果糖、异构化液糖、甘草甜素、甜菊、天冬氨酰苯丙氨酸甲酯、果糖低聚糖、半乳糖低聚糖等。作为酸味剂,除天然成分中提取出的果汁外,可以举出柠檬酸、酒石酸、苹果酸、乳酸、富马酸、磷酸等。柠檬酸或苹果酸在饮料中可以含有0.1~5g/L,优选含有0.5~2g/L。作为防氧化剂可以举出L-抗坏血酸、L-抗坏血酸钠、异抗坏血酸、异抗坏血酸钠。饮料中可以含有0.005~0.5质量%,优选含有0.01~0.1质量%。
本发明涉及的功能性饮料所使用的容器与一般饮料同样,可以是以聚对苯二甲酸乙二醇酯为主成分的成形容器(即PET瓶)、金属罐、与金属箔或塑料薄膜复合的纸容器、瓶等通常的形态。
并且上述的容器,例如,就金属罐这样在填装于容器后可以加热杀菌的情况来说,按食品卫生法规定的杀菌条件制造。关于PET瓶、纸容器这样的不能进行蒸馏罐杀菌的容器,采用预先按与上述相同的杀菌条件如用平板式热交换器等高温短时间杀菌后,冷却到一定温度再填装容器的方法。另外,可以在无菌条件下,向已填装的容器中混合其它成分来添加。进而,可以进行在酸性条件下加热杀菌后在无菌条件下使pH值恢复至中性或在中性条件下加热杀菌后在无菌条件下使pH值恢复至酸性等的操作。
组合物的制造
本发明涉及的组合物为,以来源于规定的茶叶的甲基儿茶酸成分作为过敏性鼻炎抑制有效成分及中性脂肪减少剂的组合物。该组合物是使用以往公知的方法从茶叶中提取甲基儿茶酸得到的。提取时的温度只要高于溶媒的融点低于溶媒的沸点,则没有特别的限定,优选对于水是10℃~100℃,对于乙醇和甲醇是10℃~40℃。提取时间优选10秒~24小时的范围。
例如,优选向通过破碎、粉碎等将干燥茶叶进行粉末化处理后的物质中添加提取溶媒,作为提取物或其处理物使用。作为提取溶媒可以举出水;低级醇类,例如甲醇、乙醇、丙醇、异丙醇、丁醇、异丁醇;醚类,例如乙醚、二恶烷;酮类,例如丙酮等,优选水、乙醇、或水-乙醇混合溶媒。
得到的提取物,也可以直接用作本发明涉及的组合物,但优选使用一般作为化学分离精制手段的方法。例如,可以使用液-液分配色谱、薄层柱色谱、吸附柱色谱、分配柱色谱、凝胶过滤主色谱、离子交换柱色谱、电泳或高效液相色谱等。另外,也可以根据需要将这些分离精制手段组合使用。
本发明涉及的组合物可以用于医药、食品等各种用途。作为医药,可以用于过敏性鼻炎或高脂血症、肥胖症、肝胆疾病的治疗目的。作为食品,可以作为食品添加剂与特定保健用食品、特殊营养食品、营养辅助食品、健康食品等混合。作为添加对象的食品可以是各种食品。作为饮料,可以与作为特定保健用食品、特殊营养食品、营养辅助食品的饮料或其它的营养饮料、健康饮料、各种的健康茶、其它的饮料等混合。作为其他食品可以举出点心类、面包、面类、大豆加工品、乳制品、蛋加工品、鱼肉熟食品、油脂、调味料等。作为化妆品,出于缓和或预防花粉症症状的目的或瘦身的目的,可以向护肤品、粉底霜或化妆品中添加本发明涉及的组合物。
关于医药,本发明涉及的组合物可以直接或用水等稀释后,经口给药。或者通过将该物质与公知的医药用载体一起制剂化进行调制。例如,作为糖浆等口服液体制剂,或加工成提取物、粉末等,与药学上可接受的载体混合,作为片剂、胶囊剂、颗粒剂、散剂等口服固体制剂给药。作为药学上可接受的载体,作为制剂原料可以使用惯用的各种有机或无机载体物质,固体制剂中混合赋形剂、润滑剂、粘结剂、崩解剂,液体制剂中混合溶剂、赋形剂、悬浊化剂、粘结剂等。另外,根据需要,可以使用防腐剂、抗氧化剂、着色剂、甜味剂等制剂添加剂。进一步,可以使用公知的医药用载体,制成鼻腔清洗剂、滴鼻药或眼睛清洗剂等。
实施例
[实施例1:过敏性鼻炎的抑制效果的研究]
将茶叶“红富贵”用30倍量的纯水90℃进行提取得到的提取液,添加混合碳酸氢钠等水质调节剂及维生素C。杀菌,向密封容器(本实施例中为250ml纸包)中充氮填装,制成试验饮料1。
[比较例1]
作为比较例,使甲基儿茶酸以外的成分含量与试验饮料1等量,将茶叶“薮北(やぶきた)”用纯水调配,添加混合碳酸氢钠等水质调节剂、维生素C。将混合液杀菌,向密封容器中充氮填装制成试验饮料2。
[比较例2]
作为比较例,甲基儿茶酸以外的成分含量与试验饮料1等量,将“麦茶”用纯水调配,添加混合碳酸氢钠等水质调节剂、维生素C。将混合液杀菌,向密封容器中充氮填装制成试验饮料3。
试验饮料1至3中所含的甲基儿茶酸的含量如表1所示。
表1
(mg/100ml) | 试验饮料1 | 试验饮料2 | 试验饮料3 |
甲基儿茶酸总量 | 8.1 | 0 | 0 |
总儿茶酸含量 | 104.8 | 109.2 | 0 |
[实施例2:过敏性鼻炎抑制效果的研究]
对实施例1及比较例1、2中制造的试验饮料,进行是否抑制花粉症状的试验。试验时,将轻度的全年性鼻炎患者20~23名为一组,使各组摄取试验饮料1~3十二周,调查对鼻炎症状的影响。试验委托综合医科学研究所,试验的协议书由综合医科学研究所与朝日饮料株式会社、朝日啤酒株式会社、独立行政法人农业·生物系特定产业技术研究机构共同设计。
让受试者饮用试验饮料1~3各自250ml容器装的饮料,1日2杯(500ml/日)。让受试者自饮用开始2周前至饮用期终止4周后(第16周)每天记录过敏日志,按照日本过敏学会的诊断基准算出重症度分数。试验进行双盲检验(受试者和主治医师双方都不知道其所属的试验组)。每3周将数值平均化,算出外观上的鼻炎重症度(Nasal Symptomatic Score),其结果如图1所示。图中的记号,四方形表示试验饮料1,圆表示试验饮料2,三角形表示试验饮料3。
饮用开始第6周以后,与作为对照组的试验饮料2和3的两组中的症状恢复的情况相对,试验饮料1组中维持症状的改善。
另外,发现鼻液中嗜曙红细胞数也减少了。据此,“红富贵”的过敏改善作用超过“麦茶”、“薮北”,验证了“红富贵”的有效性。其结果如图2所示。而且,与图1相同,图中四方形表示试验饮料1,圆表示试验饮料2,三角形表示试验饮料3。据此,可以提供确认了对过敏性鼻炎的个体效果的过敏性鼻炎抑制饮料。
[实施例3:中性脂肪的减少效果的研究]
将10名空腹时中性脂肪值为100~350mg/dL的健康成年人分为2组,每组5名(均为男性4名、女性1名),让其摄取试验饮料1或比较例2中的试验饮料3六周。各饮料装入250ml的容器,1日饮用2杯(500ml/日)。测定试验开始时和饮用终止时的一晚禁食后的中性脂肪值(平均±SD值)。此时的结果如表2及图3所示。这样,与不含甲基儿茶酸的试验饮料3的摄取不影响血清中性脂肪值相对,含有甲基儿茶酸的试验饮料1可使中性脂肪值显著下降。
表2
0周 | 6周 | |
试验饮料1(红富贵) | 174±82 | 125±62 |
试验饮料3(麦茶) | 174±31 | 181±42 |
*对于0周p<0.05
[实施例4:肝胆功能的是非结果的研究]
将9名总胆红素值1.1的全年性过敏性鼻炎患者分为2组,一组5名(红富贵),一组4名(安慰剂:薮北),让其摄取实施例1中的试验饮料1或比较例1中的试验饮料2四周。各饮料装入250ml的容器中,1日饮用6杯(150ml/日)。测定试验开始时和饮用终止时的一晚禁食后的总胆红素值(平均±SD值)。此时的结果如表3和图4所示。据此确认其起到了作为抗高脂血症剂及肝胆功能改善剂的效果。
表3
0周 | 6周 | |
试验饮料1(红富贵) | 1.34±0.20 | 1.06±0.29 |
试验饮料2(薮北) | 1.13±0.12 | 1.15±0.3 |
*对于0周p<0.05
Claims (7)
2.根据权利要求1记载的功能性饮料,其中,所述功能性饮料是提取茶叶得到的饮料。
3.根据权利要求1或2记载的功能性饮料,其中,相对于所述功能性饮料每100ml,含有所述甲基儿茶酸1mg~30mg。
4.根据权利要求1至3中的任一项记载的功能性饮料,其中,所述甲基儿茶酸是来源于“红富贵”、“红富士”、“红誉”、“八重穗”、“骏河早生”、“丰绿”、“金谷绿”、“奥武藏”、“青心大有”、“青心乌龙”、“大叶乌龙”、“红花”、“红光”、“山峡”、“山绿”、“唐红”、“香骏”、“仓风”及“奥绿”或它们的混合物的茶叶的物质。
5.根据权利要求1至4中的任一项记载的功能性饮料,其中,所述功能性饮料是被附加了为抑制过敏性鼻炎而使用的意思表示和/或因对于高脂血症、肝胆功能改善有效而使用的意思表示的物质。
7.根据权利要求6记载的组合物,其中,所述组合物是饮食品、内服药、涂布药、鼻腔清洗剂、滴鼻药、化妆品、或眼睛的清洗剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP030490/2004 | 2004-02-06 | ||
JP2004030490 | 2004-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1913911A true CN1913911A (zh) | 2007-02-14 |
Family
ID=34835999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800038099A Pending CN1913911A (zh) | 2004-02-06 | 2005-02-04 | 功能性饮料及组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070128299A1 (zh) |
JP (3) | JPWO2005074960A1 (zh) |
KR (2) | KR100842634B1 (zh) |
CN (1) | CN1913911A (zh) |
WO (1) | WO2005074960A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007077097A (ja) * | 2005-09-15 | 2007-03-29 | Tsumura & Co | 鼻用組成物 |
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
JP4997523B2 (ja) * | 2006-01-13 | 2012-08-08 | 独立行政法人農業・食品産業技術総合研究機構 | 抗アレルギー剤及びこれを含有する飲食品、外用剤、化粧料 |
JP2007320864A (ja) * | 2006-05-30 | 2007-12-13 | Toshihiko Osawa | 非アルコール性脂肪肝炎予防・治療用組成物 |
JP2008094797A (ja) * | 2006-10-16 | 2008-04-24 | Morinaga & Co Ltd | 肥満抑制剤及び該肥満抑制剤を含む高脂肪含有飲食品 |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
JP2008178319A (ja) * | 2007-01-23 | 2008-08-07 | Asahi Soft Drinks Co Ltd | 容器入り茶飲料群の製造方法 |
JP5424533B2 (ja) * | 2007-01-23 | 2014-02-26 | アサヒ飲料株式会社 | 容器入り茶飲料群の製造方法 |
JP5128826B2 (ja) * | 2007-02-07 | 2013-01-23 | 独立行政法人農業・食品産業技術総合研究機構 | 新規なメチル化カテキン及びそれを含む組成 |
FR2923718B1 (fr) * | 2007-11-15 | 2009-12-18 | Caudalie | Compositions de derives polyphenoliques flavonoidiques et leurs applications pour lutter contre les pathologies et le vieillissement des organismes vivants |
WO2009119113A1 (ja) * | 2008-03-28 | 2009-10-01 | 静岡県公立大学法人 | メチル化カテキン含有発酵茶飲料 |
WO2011042958A1 (ja) * | 2009-10-06 | 2011-04-14 | 森永製菓株式会社 | ポリフェノール類化合物の吸収促進剤及びその利用 |
JP2012031101A (ja) * | 2010-07-30 | 2012-02-16 | Kurume Univ | 非アルコール性脂肪性肝炎の改善用組成物 |
JP6105940B2 (ja) * | 2013-01-09 | 2017-03-29 | アサヒ飲料株式会社 | 酸性飲料及び耐熱性好酸性菌の増殖抑制方法 |
CN109221551A (zh) * | 2018-11-20 | 2019-01-18 | 广西中医药大学 | 一种降血脂抗氧化保健茶及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6232842A (ja) * | 1985-08-05 | 1987-02-12 | Norin Suisansyo Chiyagiyou Shikenjo | 遠赤外線による半醗酵茶の製造法 |
JPH06101096B2 (ja) * | 1987-02-18 | 1994-12-12 | 三洋電機株式会社 | 磁気ヘッド |
JP3546312B2 (ja) * | 1994-02-18 | 2004-07-28 | 二六 村松 | 紅茶等の製造工程における茶葉の発酵方法 |
JPH10234301A (ja) * | 1997-02-27 | 1998-09-08 | Meiji Seika Kaisha Ltd | 緑茶飲料 |
JPH11107A (ja) * | 1997-06-12 | 1999-01-06 | Res Inst For Prod Dev | 高カテキン類含有チャ葉 |
JP3038373B2 (ja) * | 1997-10-29 | 2000-05-08 | 農林水産省 野菜・茶業試験場長 | γ−アミノ酪酸含量の高い茶の製造法 |
JP3724618B2 (ja) * | 1997-11-18 | 2005-12-07 | 株式会社ファンケル | グミキャンデイ組成物 |
JP3637355B2 (ja) * | 1998-11-20 | 2005-04-13 | 独立行政法人農業・生物系特定産業技術研究機構 | 抗アレルギー剤 |
JP3569180B2 (ja) * | 1999-11-19 | 2004-09-22 | 株式会社 伊藤園 | 茶の苦渋味低減方法 |
JP2001253879A (ja) * | 2000-03-09 | 2001-09-18 | Shizuoka Prefecture | カテキン類のアルキル誘導体 |
JP3403400B1 (ja) * | 2001-09-28 | 2003-05-06 | 花王株式会社 | 容器詰飲料 |
JP2003171297A (ja) * | 2001-12-07 | 2003-06-17 | Ito En Ltd | 血中ビリルビン濃度低下剤及び黄疸治療・予防剤 |
JP2004105078A (ja) * | 2002-09-18 | 2004-04-08 | Bio Oriented Technol Res Advancement Inst | 抗アレルギー成分を含有する機能性飲食品 |
US20040202732A1 (en) * | 2003-04-11 | 2004-10-14 | Brown William Stewart | Composition to promote weight loss |
JP2004337110A (ja) * | 2003-05-19 | 2004-12-02 | Mitsui Norin Co Ltd | 細胞保護剤およびその保護方法 |
-
2005
- 2005-02-04 KR KR1020087000171A patent/KR100842634B1/ko not_active IP Right Cessation
- 2005-02-04 US US10/588,428 patent/US20070128299A1/en not_active Abandoned
- 2005-02-04 WO PCT/JP2005/001700 patent/WO2005074960A1/ja active Application Filing
- 2005-02-04 KR KR1020067017985A patent/KR100841834B1/ko not_active IP Right Cessation
- 2005-02-04 CN CNA2005800038099A patent/CN1913911A/zh active Pending
- 2005-02-04 JP JP2005517749A patent/JPWO2005074960A1/ja active Pending
-
2010
- 2010-11-04 JP JP2010247334A patent/JP5825772B2/ja active Active
-
2014
- 2014-01-28 JP JP2014013461A patent/JP2014114303A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPWO2005074960A1 (ja) | 2007-09-13 |
JP2011021040A (ja) | 2011-02-03 |
WO2005074960A1 (ja) | 2005-08-18 |
US20070128299A1 (en) | 2007-06-07 |
KR20060115767A (ko) | 2006-11-09 |
JP2014114303A (ja) | 2014-06-26 |
JP5825772B2 (ja) | 2015-12-02 |
KR100842634B1 (ko) | 2008-06-30 |
KR100841834B1 (ko) | 2008-06-26 |
KR20080014145A (ko) | 2008-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1913911A (zh) | 功能性饮料及组合物 | |
JP6684966B2 (ja) | 新規なラクトバチルス・サケイ及びそれを含む組成物 | |
WO2006001278A1 (ja) | Ampk活性化剤 | |
US20210290693A1 (en) | Water-soluble and water-insoluble propolis products with high antioxidant capacity and their production methods | |
JP5261808B2 (ja) | 脂肪蓄積抑制剤、医薬品及び脂肪蓄積抑制作用を新たに付与する方法 | |
JP2022031912A (ja) | 経口組成物 | |
US20180296615A1 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
KR101446528B1 (ko) | 흑마늘 발효 식초 조성물 및 그 제조방법 | |
EP3834628A1 (en) | Composition for improving intestinal environment and method for improving intestinal flora | |
JP2015502954A (ja) | アギタケの水抽出物を有効成分として含有する脂質異常症の予防又は治療用の組成物 | |
JP2006335725A (ja) | 血流改善用組成物 | |
JP7090849B2 (ja) | 肝機能改善用組成物及び肝機能改善用食品組成物 | |
KR101350046B1 (ko) | 항비만 효능을 갖는 복합 생약 발효 식초 조성물 및 그 제조방법 | |
JP6841444B2 (ja) | 免疫賦活剤 | |
JP6742608B2 (ja) | 食品組成物 | |
JP2010180141A (ja) | 抗アレルギー組成物 | |
TW200908992A (en) | Anti-fatigue agent | |
JP2001046019A (ja) | 柑橘系由来の栄養組成物 | |
JP2019180412A (ja) | 経口組成物 | |
KR101752204B1 (ko) | 체중감소 및 피부미용 증진 효과가 있는 체중조절용 식품 및 그 식품의 제조방법 | |
JP7015308B2 (ja) | 小腸上皮細胞でのカテキン吸収増進剤 | |
US20070264314A1 (en) | Process and formula for treating irritable bowel syndrome | |
JP5297867B2 (ja) | モロヘイヤ抽出物を含有する抗疲労剤又は体力向上剤 | |
JP7401082B2 (ja) | 経口組成物 | |
JP2015010041A (ja) | 抗アレルギー剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1098956 Country of ref document: HK |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20070214 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1098956 Country of ref document: HK |